Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic D

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic D

Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $18 at Mizuho

May 15, 2024 5:18 AM EDT

Mizuho analyst Uy Ear raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $18.00 (from $17.00) while maintaining a Buy rating.

The analyst comments "1Q24 was strong, with Zoryve (Cream + Foam) beating our above-Consensus forecasts driven by significantly better-than-expected gross-to-nets (GtN),... More